CCRM News
-
Toronto Centre Solving Cell Manufacturing Challenges To Benefit Patients And Global Industry
6/2/2020
With Health Canada and the Food and Drug Administration beginning to approve and reimburse cell and gene therapies in significant numbers, the demand for cell and viral vector manufacturing will continue to grow.
-
Innovation Economy Council Formed To Drive Canada’s Technology Economy Post-Pandemic
4/29/2020
The founders of the newly established Innovation Economy Council (IEC) — MaRS, OCE, Communitech, DMZ, Invest Ottawa and CCRM — have published the group’s first white paper: The post-viral pivot: How Canada’s tech startups can drive the recovery from COVID-19.
-
New iPSC Master Cell Banks To Accelerate Development Of Novel Cell Therapies
4/21/2020
Toronto-based panCELLa and CCRM have executed a collaboration agreement using novel technology to generate commercial-use and clinical-grade iPSC lines which will be made available to academia and industry to enable the development of new therapies.
-
Avectas And CCRM Announce Collaboration To Accelerate Development Of Novel Technology For Cell Therapies
3/3/2020
Avectas, a cell engineering technology business, and CCRM, a leader in developing and commercializing cell and gene therapies, today announced they have entered into a collaboration to accelerate the translation of Avectas’ non-viral cell engineering platform (Solupore®) into the clinic.
-
New Project To Advance Platelet-Based Therapeutics For Patients
1/28/2020
There is a chronic global shortage of platelets to treat patients who are actively bleeding due to trauma or surgery, those undergoing treatments for cancer, or those with low platelet counts due to a variety of conditions – essentially anyone who needs to prevent life-threatening bleeding.